Krystal Biotech Inc (KRYS)
177.41
-6.81
(-3.70%)
USD |
NASDAQ |
Nov 14, 16:00
177.41
0.00 (0.00%)
After-Hours: 20:00
Krystal Biotech Cash from Investing (Quarterly): -34.33M for Sept. 30, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -34.33M |
| June 30, 2024 | -19.35M |
| March 31, 2024 | -25.98M |
| December 31, 2023 | -10.16M |
| September 30, 2023 | 105.19M |
| June 30, 2023 | -15.96M |
| March 31, 2023 | 3.563M |
| December 31, 2022 | -5.208M |
| September 30, 2022 | -14.74M |
| June 30, 2022 | -38.22M |
| March 31, 2022 | -55.91M |
| December 31, 2021 | -126.54M |
| September 30, 2021 | -37.17M |
| June 30, 2021 | -62.32M |
| March 31, 2021 | -0.747M |
| December 31, 2020 | -6.217M |
| Date | Value |
|---|---|
| September 30, 2020 | -2.697M |
| June 30, 2020 | -0.962M |
| March 31, 2020 | -1.305M |
| December 31, 2019 | -0.591M |
| September 30, 2019 | -0.682M |
| June 30, 2019 | -1.236M |
| March 31, 2019 | -2.482M |
| December 31, 2018 | -3.767M |
| September 30, 2018 | -2.755M |
| June 30, 2018 | -3.801M |
| March 31, 2018 | 0.00 |
| December 31, 2017 | -0.159M |
| September 30, 2017 | -0.012M |
| June 30, 2017 | -0.032M |
| March 31, 2017 | -0.007M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-126.54M
Minimum
Dec 2021
105.19M
Maximum
Sep 2023
-17.48M
Average
-12.45M
Median
Cash from Investing (Quarterly) Benchmarks
| Bioventus Inc | -0.064M |
| ADMA Biologics Inc | -1.098M |
| Alnylam Pharmaceuticals Inc | -30.25M |
| Amicus Therapeutics Inc | 34.27M |
| Apellis Pharmaceuticals Inc | 0.00 |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 58.86M |
| Cash from Financing (Quarterly) | 3.365M |
| Free Cash Flow | 58.06M |
| Free Cash Flow Per Share (Quarterly) | 1.933 |
| Free Cash Flow to Equity (Quarterly) | 57.81M |
| Free Cash Flow to Firm (Quarterly) | 57.81M |
| Free Cash Flow Yield | 1.11% |